In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey

Yıl: 2022 Cilt: 33 Sayı: 11 Sayfa Aralığı: 971 - 978 Metin Dili: İngilizce DOI: 10.5152/tjg.2022.21834 İndeks Tarihi: 25-05-2023

In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey

Öz:
Background: People who inject drugs (PWID) should be treated in order to eliminate hepatitis C virus in the world. The aim of this study was to compare direct-acting antivirals treatment of hepatitis C virus for PWID and non-PWID in a real-life setting. Methods: We performed a prospective, non-randomized, observational multicenter cohort study in 37 centers. All patients treated with direct-acting antivirals between April 1, 2017, and February 28, 2019, were included. In total, 2713 patients were included in the study among which 250 were PWID and 2463 were non-PWID. Besides patient characteristics, treatment response, follow-up, and side effects of treatment were also analyzed. Results: Genotype 1a and 3 were more prevalent in PWID-infected patients (20.4% vs 9.9% and 46.8% vs 5.3%). The number of naïve patients was higher in PWID (90.7% vs 60.0%), while the number of patients with cirrhosis was higher in non-PWID (14.1% vs 3.7%). The loss of follow-up was higher in PWID (29.6% vs 13.6%). There was no difference in the sustained virologic response at 12 weeks after treatment (98.3% vs 98.4%), but the end of treatment response was lower in PWID (96.2% vs 99.0%). In addition, the rate of treatment completion was lower in PWID (74% vs 94.4%). Conclusion: Direct-acting antivirals were safe and effective in PWID. Primary measures should be taken to prevent the loss of follow-up and poor adherence in PWID patients in order to achieve World Health Organization’s objective of eliminating viral hepatitis.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
0
0
0
  • 1. Lee MH, Yang HI, Lu SN, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012;206(4):469-477. [CrossRef]
  • 2. https://www.who.int/en/news-room/fact-sheets/detail/hepatiti s-c. Accessed October 21, 2019.
  • 3. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378(9791):571-583. [CrossRef]
  • 4. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural his tory of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10(9):553- 562. [CrossRef]
  • 5. Grebely J, Matthews GV, Dore GJ. Treatment of acute HCV infection. Nat Rev Gastroenterol Hepatol. 2011;8(5):265-274. [CrossRef]
  • 6. Tozun N, Ozdogan O, Cakaloglu Y, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect. 2015;21(11):1020- 1026. [CrossRef]
  • 7. Altuğlu I, Tanyeri S, Zeytinoğlu A, Altintoprak AE. HBsAg, anti-HCV and anti-HIV seroprevalance among drug users: a retrospective assessment. Noro Psikiyatr Ars. 2019;56(3):186-190. [CrossRef]
  • 8. Turkey drug report pdf Ministry of Interior, General Directorate of Security, Department of Combating Narcotic Crime ANKARA; 2019. Available at: http://www.narkotik.pol.tr. Accessed Novomber 21, 2019.
  • 9. Rodriguez-Torres M, Lawitz E, Kowdley KV, et al. Sofosbuvir (GS 7977) plus peginterferon/ribavirin in treatment-naive patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial. J Hepa tol. 2013;58(4):663-668. [CrossRef]
  • 10. Sarıgül F, Sayan M, Üser U, Oztoprak N. Evaluation of direct act ing antivirals efficiency in Turkish patients with chronic hepatitis C under strict rules. Hepat Mon. 2019:e62390. [CrossRef]
  • 11. Pecoraro V, Banzi R, Cariani E, et al. New direct-acting antivirals for the treatment of patients with hepatitis C virus infection: a systematic review of randomized controlled trials. J Clin Exp Hepatol. 2019;9(4):522-538. [CrossRef]
  • 12. World Health Organisation. Global Health Sector Strategy on Viral Hepatitis 2016-2021; 2017. Available at: http://apps.who.int/ iris/bitstream/10665/246177/1/WHO-HIV-2016.06-eng.pdf?ua=1. Accessed November 11, 2019.
  • 13. Health Ministry of Turkey. Health Implementation Guideline; 2017:30018. Available at: http://www.sgk.gov.tr. Accessed November 11, 2019.
  • 14. Health Ministry of Turkey. Health Implementation Guideline; 2018:30018. Available at: http://www.sgk.gov.tr. Accessed November 11, 2019.
  • 15. Falade-Nwulia O, Sulkowski MS, Merkow A, Latkin C, Mehta SH. Understanding and addressing hepatitis C reinfection in the oral direct-acting antiviral era. J Viral Hepat. 2018;25(3):220-227. [CrossRef]
  • 16. Grebely J, Alavi M, Micallef M, et al. Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitu tion treatment and community health clinics: the ETHOS Study. Addiction. 2016;111(2):311-319. [CrossRef]
  • 17. Ghany MG, Marks KM, Morgan TR, et al. Hepatitis C Guidance 2019 Update: AASLD-IDSA Recommendations for Testing, Manag ing, and Treating Hepatitis C Virus Infection. Hepatology 2019. [CrossRef]. Accessed November 21, 2019.
  • 18. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C European association for the study of the liver. Electronic address: easloffice@ easloffice.eu. European Association for the Study of the Liver. J Hepa tol. 2018;69(2):461-511. [CrossRef]. Accessed Novomber 21, 2019.
  • 19. Marinho RT, Barreira DP. Hepatitis C, stigma and cure. World J Gastroenterol. 2013;19(40):6703-6709. [CrossRef]
  • 20. Grebely J, Dore GJ. Can hepatitis C virus infection be eradicated in people who inject drugs? Antiviral Res. 2014;104:62-72. [CrossRef]
  • 21. Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. Harm Reduct J. 2013;10:7. [CrossRef]
  • 22. Robaeys G, Bielen R, Azar DG, Razavi H, Nevens F. Global Geno type distribution of hepatitis C viral infection among people who inject drugs Hepatol. J Hepatol. 2016;65(6):1094-1103. [CrossRef]
  • 23. Alagoz KG, Karataylı CS, Karataylı E, Çelik E, et al. Hepatitis C virüs genotype distribution in Turkey remains unchanged after a decade: performance of phylogenetic analysis of the NS5B, E1, and 5’UTR regions in genotyping efficiency. Turk J Gastroenterol. 2014;25(4);405-410.
  • 24. Üçbilek E, Abayli B, Koyuncu MB, et al. Distribution of hepatitis C virus genotypes among intravenous drug users in the Çukurova region of Turkey. Turk J Med Sci. 2016;46(1):66-71. [CrossRef]
  • 25. Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology. 2000;31(1):241-246. [CrossRef]
  • 26. Bielen R, Moreno C, Van Vlierberghe HV, Bourgeoisd S, et al. Bel gian experience with direct acting antivirals in people who inject drugs. Drug Alcohol Depend. 2017;177:214-220. [CrossRef]
  • 27. Bouscaillou J, Kikvidze T, Butsashvili M, et al. Direct acting anti viral-based treatment of hepatitis C virus infection among people who inject drugs in Georgia: a prospective cohort study. Int J Drug Policy. 2018;62:104-111. [CrossRef]
  • 28. Luhmann N, Champagnat J, Golovin S, et al. Access to hepatitis C treatment for people who inject drugs in low- and middle-income settings: evidence from 5 countries in Eastern Europe and Asia. Int J Drug Policy. 2015;26(11):1081-1087. [CrossRef]
  • 29. Boglione L, Mornese Pinna S, De Nicolò A, et al. Treatment with direct-acting antiviral agents of hepatitis C virus infection in inject ing drug users: a prospective study. J Viral Hepat. 2017;24(10):850- 857. [CrossRef]
  • 30. Grebely J, Dalgard O, Conway B, et al. Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infec tion and recent injecting drug use: the SIMPLIFY study. J Hepatol. 2017;66(1):513. [CrossRef]
  • 31. Hajarizadeh B, Cunningham EB, Reid H, Law M, Dore GJ, Gre bely J. Direct-acting antiviral treatment for hepatitis C among peo ple who use or inject drugs: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2018;3(11):754-767. [CrossRef]
  • 32. Hepatitis C Epidemiology in New York State. Available at: https ://www.health.ny.gov/diseases/communicable/hepatitis/hepatit is_c/docs/taskforce/epidemiology.pdf. Accessed Novomber 21, 2019.
  • 33. Grebely J, Raffa JD, Meagher C, et al. Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. J Gastroenterol Hepatol. 2007;22(9):1519-1525. [CrossRef]
  • 34. Dore GJ, Hellard M, Matthews GV, et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infec tion. Gastroenterology. 2010;138(1):123-35.e1. [CrossRef]
  • 35. Grebely J, Robaeys G, Bruggmann P, et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Int J Drug Policy. 2015;26(10):1028-1038. [CrossRef]
  • 36. American Association for the Study of Liver Diseases/Infectious Diseases Society of America. Recommendations for testing, manag ing, and treating hepatitis C; 2015. Available at: [CrossRef]. Accessed November 21, 2019.
  • 37. McPhee F. Developments in the treatment of HCV genotype 3 infection. Expert Rev Anti Infect Ther. 2019;17(10):775-785. [CrossRef]
  • 38. Llerena S, Cabezas J, Cuadrado A, et al. Rescue Therapy for Gen otype-3 DAA Non-responders, Almost all Done. Ann Hepatol. 2019;18(1):236-239. [CrossRef]
  • 39. Hajarizadeh B, Cunningham EB, Valerio H, et al. Hepatitis C rein fection after successful antiviral treatment among people who inject drugs: A meta-analysis. J Hepatol. 2020;72(4):643-657. [CrossRef]
  • 40. Dore GJ, Altice F, Litwin AH, et al. Elbasvir/grazoprevir to treat HCV infection in persons receiving opioid agonist therapy: a rand omized controlled trial (C-EDGE CO-STAR). Ann Intern Med. 2016;165(9):625-634. [CrossRef]
  • 41. Scherz N, Brunner N, Bruggmann P. Direct-acting antivirals for hepatitis C in patient in opioid substitution treatment and heroin assisted treatment: real-life data. Int J Drug Policy. 2018;62:74-77.
  • 42. Panagiotoglou D, Krebs E, Min JE, et al. Initiating HCV treatment with direct acting agents in opioid agonist treatment:when to start fo r people co-infected with HIV? Int J Drug Policy. 2017;47:169-176. [CrossRef]
  • 43. Akselrod H, Grau LE, Barbour R, Heimer R. Seroprevalence of HIV, hepatitis B virus, and HCV among injection drug users in Connecti cut: understanding infection and coinfection risks in a nonurban population. Am J Public Health. 2014;104(9):1713-1721. [CrossRef]
  • 44. Oyaro M, Wylie J, Chen CY, Ondondo RO, Kramvis A. Human immunodeficiency virus infection predictors and genetic diversity of hepatitis B virus and hepatitis C virus co-infections among drug users in three major Kenyan cities. South Afr J HIV Med. 2018;19(1):737. [CrossRef]
  • 45. Hernandez MD, Sherman KE. HIV/hepatitis C coinfection natural history and disease progression. Curr Opin HIV AIDS. 2011;6(6):478- 482. [CrossRef]
  • 46. Kourtis AP, Bulterys M, Hu DJ, Jamieson DJ. HIV-HBV coinfec tion–a global challenge. N Engl J Med. 2012;366(19):1749-1752. [CrossRef]
  • 47. Khatib A, Matiko E, Khalid F, et al. HIV and hepatitis B and C co-infection among people who inject drugs in Zanzibar. BMC Public Health. 2017;17(1):917. [CrossRef]
APA Sarıgül F, User U, Didem sarı N, Kurtaran B, ONLEN Y, Şenateş E, Gunduz A, zerdali e, KARSEN H, Batirel A, KARAALİ R, GÜNER R, Yamazhan T, köse ş, Erben N, Ince N, Koksal I, Oztoprak N, Yörük G, komur s, Bal T, Yıldız Kaya S, bozkurt i, Gunal O, YILDIZ I, İNAN D, Barut S, NAMIDURU M, Tosun S, Türker K, Sener A, hizel k, Baykam N, Duygu F, Bodur H, Can G, GÜL H, SAĞMAK TARTAR A, Celebi G, Sunnetcioglu M, KARABAY O, kumbasar karaosmanoglu h, SIRMATEL F, Tabak F (2022). In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey. , 971 - 978. 10.5152/tjg.2022.21834
Chicago Sarıgül Figen,User Ulku,Didem sarı Nagehan,Kurtaran Behice,ONLEN YÜSÜF,Şenateş Ebubekir,Gunduz Alper,zerdali esra,KARSEN HASAN,Batirel Ayse,KARAALİ Rıdvan,GÜNER RAHMET,Yamazhan Tansu,köse şükran,Erben Nurettin,Ince Nevin,Koksal Iftihar,Oztoprak Nefise,Yörük Gülşen,komur suheyla,Bal Tayibe,Yıldız Kaya Sibel,bozkurt ilkay,Gunal Ozgur,YILDIZ ILKNUR ESEN,İNAN DİLARA,Barut Sener,NAMIDURU Mustafa,Tosun Selma,Türker Kamuran,Sener Alper,hizel kenan,Baykam Nurcan,Duygu Fazilet,Bodur Hurrem,Can Güray,GÜL Hanefi Cem,SAĞMAK TARTAR Ayşe,Celebi Guven,Sunnetcioglu Mahmut,KARABAY OĞUZ,kumbasar karaosmanoglu hayat,SIRMATEL FATMA,Tabak Fehmi In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey. (2022): 971 - 978. 10.5152/tjg.2022.21834
MLA Sarıgül Figen,User Ulku,Didem sarı Nagehan,Kurtaran Behice,ONLEN YÜSÜF,Şenateş Ebubekir,Gunduz Alper,zerdali esra,KARSEN HASAN,Batirel Ayse,KARAALİ Rıdvan,GÜNER RAHMET,Yamazhan Tansu,köse şükran,Erben Nurettin,Ince Nevin,Koksal Iftihar,Oztoprak Nefise,Yörük Gülşen,komur suheyla,Bal Tayibe,Yıldız Kaya Sibel,bozkurt ilkay,Gunal Ozgur,YILDIZ ILKNUR ESEN,İNAN DİLARA,Barut Sener,NAMIDURU Mustafa,Tosun Selma,Türker Kamuran,Sener Alper,hizel kenan,Baykam Nurcan,Duygu Fazilet,Bodur Hurrem,Can Güray,GÜL Hanefi Cem,SAĞMAK TARTAR Ayşe,Celebi Guven,Sunnetcioglu Mahmut,KARABAY OĞUZ,kumbasar karaosmanoglu hayat,SIRMATEL FATMA,Tabak Fehmi In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey. , 2022, ss.971 - 978. 10.5152/tjg.2022.21834
AMA Sarıgül F,User U,Didem sarı N,Kurtaran B,ONLEN Y,Şenateş E,Gunduz A,zerdali e,KARSEN H,Batirel A,KARAALİ R,GÜNER R,Yamazhan T,köse ş,Erben N,Ince N,Koksal I,Oztoprak N,Yörük G,komur s,Bal T,Yıldız Kaya S,bozkurt i,Gunal O,YILDIZ I,İNAN D,Barut S,NAMIDURU M,Tosun S,Türker K,Sener A,hizel k,Baykam N,Duygu F,Bodur H,Can G,GÜL H,SAĞMAK TARTAR A,Celebi G,Sunnetcioglu M,KARABAY O,kumbasar karaosmanoglu h,SIRMATEL F,Tabak F In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey. . 2022; 971 - 978. 10.5152/tjg.2022.21834
Vancouver Sarıgül F,User U,Didem sarı N,Kurtaran B,ONLEN Y,Şenateş E,Gunduz A,zerdali e,KARSEN H,Batirel A,KARAALİ R,GÜNER R,Yamazhan T,köse ş,Erben N,Ince N,Koksal I,Oztoprak N,Yörük G,komur s,Bal T,Yıldız Kaya S,bozkurt i,Gunal O,YILDIZ I,İNAN D,Barut S,NAMIDURU M,Tosun S,Türker K,Sener A,hizel k,Baykam N,Duygu F,Bodur H,Can G,GÜL H,SAĞMAK TARTAR A,Celebi G,Sunnetcioglu M,KARABAY O,kumbasar karaosmanoglu h,SIRMATEL F,Tabak F In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey. . 2022; 971 - 978. 10.5152/tjg.2022.21834
IEEE Sarıgül F,User U,Didem sarı N,Kurtaran B,ONLEN Y,Şenateş E,Gunduz A,zerdali e,KARSEN H,Batirel A,KARAALİ R,GÜNER R,Yamazhan T,köse ş,Erben N,Ince N,Koksal I,Oztoprak N,Yörük G,komur s,Bal T,Yıldız Kaya S,bozkurt i,Gunal O,YILDIZ I,İNAN D,Barut S,NAMIDURU M,Tosun S,Türker K,Sener A,hizel k,Baykam N,Duygu F,Bodur H,Can G,GÜL H,SAĞMAK TARTAR A,Celebi G,Sunnetcioglu M,KARABAY O,kumbasar karaosmanoglu h,SIRMATEL F,Tabak F "In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey." , ss.971 - 978, 2022. 10.5152/tjg.2022.21834
ISNAD Sarıgül, Figen vd. "In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey". (2022), 971-978. https://doi.org/10.5152/tjg.2022.21834
APA Sarıgül F, User U, Didem sarı N, Kurtaran B, ONLEN Y, Şenateş E, Gunduz A, zerdali e, KARSEN H, Batirel A, KARAALİ R, GÜNER R, Yamazhan T, köse ş, Erben N, Ince N, Koksal I, Oztoprak N, Yörük G, komur s, Bal T, Yıldız Kaya S, bozkurt i, Gunal O, YILDIZ I, İNAN D, Barut S, NAMIDURU M, Tosun S, Türker K, Sener A, hizel k, Baykam N, Duygu F, Bodur H, Can G, GÜL H, SAĞMAK TARTAR A, Celebi G, Sunnetcioglu M, KARABAY O, kumbasar karaosmanoglu h, SIRMATEL F, Tabak F (2022). In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey. Turkish Journal of Gastroenterology, 33(11), 971 - 978. 10.5152/tjg.2022.21834
Chicago Sarıgül Figen,User Ulku,Didem sarı Nagehan,Kurtaran Behice,ONLEN YÜSÜF,Şenateş Ebubekir,Gunduz Alper,zerdali esra,KARSEN HASAN,Batirel Ayse,KARAALİ Rıdvan,GÜNER RAHMET,Yamazhan Tansu,köse şükran,Erben Nurettin,Ince Nevin,Koksal Iftihar,Oztoprak Nefise,Yörük Gülşen,komur suheyla,Bal Tayibe,Yıldız Kaya Sibel,bozkurt ilkay,Gunal Ozgur,YILDIZ ILKNUR ESEN,İNAN DİLARA,Barut Sener,NAMIDURU Mustafa,Tosun Selma,Türker Kamuran,Sener Alper,hizel kenan,Baykam Nurcan,Duygu Fazilet,Bodur Hurrem,Can Güray,GÜL Hanefi Cem,SAĞMAK TARTAR Ayşe,Celebi Guven,Sunnetcioglu Mahmut,KARABAY OĞUZ,kumbasar karaosmanoglu hayat,SIRMATEL FATMA,Tabak Fehmi In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey. Turkish Journal of Gastroenterology 33, no.11 (2022): 971 - 978. 10.5152/tjg.2022.21834
MLA Sarıgül Figen,User Ulku,Didem sarı Nagehan,Kurtaran Behice,ONLEN YÜSÜF,Şenateş Ebubekir,Gunduz Alper,zerdali esra,KARSEN HASAN,Batirel Ayse,KARAALİ Rıdvan,GÜNER RAHMET,Yamazhan Tansu,köse şükran,Erben Nurettin,Ince Nevin,Koksal Iftihar,Oztoprak Nefise,Yörük Gülşen,komur suheyla,Bal Tayibe,Yıldız Kaya Sibel,bozkurt ilkay,Gunal Ozgur,YILDIZ ILKNUR ESEN,İNAN DİLARA,Barut Sener,NAMIDURU Mustafa,Tosun Selma,Türker Kamuran,Sener Alper,hizel kenan,Baykam Nurcan,Duygu Fazilet,Bodur Hurrem,Can Güray,GÜL Hanefi Cem,SAĞMAK TARTAR Ayşe,Celebi Guven,Sunnetcioglu Mahmut,KARABAY OĞUZ,kumbasar karaosmanoglu hayat,SIRMATEL FATMA,Tabak Fehmi In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey. Turkish Journal of Gastroenterology, vol.33, no.11, 2022, ss.971 - 978. 10.5152/tjg.2022.21834
AMA Sarıgül F,User U,Didem sarı N,Kurtaran B,ONLEN Y,Şenateş E,Gunduz A,zerdali e,KARSEN H,Batirel A,KARAALİ R,GÜNER R,Yamazhan T,köse ş,Erben N,Ince N,Koksal I,Oztoprak N,Yörük G,komur s,Bal T,Yıldız Kaya S,bozkurt i,Gunal O,YILDIZ I,İNAN D,Barut S,NAMIDURU M,Tosun S,Türker K,Sener A,hizel k,Baykam N,Duygu F,Bodur H,Can G,GÜL H,SAĞMAK TARTAR A,Celebi G,Sunnetcioglu M,KARABAY O,kumbasar karaosmanoglu h,SIRMATEL F,Tabak F In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey. Turkish Journal of Gastroenterology. 2022; 33(11): 971 - 978. 10.5152/tjg.2022.21834
Vancouver Sarıgül F,User U,Didem sarı N,Kurtaran B,ONLEN Y,Şenateş E,Gunduz A,zerdali e,KARSEN H,Batirel A,KARAALİ R,GÜNER R,Yamazhan T,köse ş,Erben N,Ince N,Koksal I,Oztoprak N,Yörük G,komur s,Bal T,Yıldız Kaya S,bozkurt i,Gunal O,YILDIZ I,İNAN D,Barut S,NAMIDURU M,Tosun S,Türker K,Sener A,hizel k,Baykam N,Duygu F,Bodur H,Can G,GÜL H,SAĞMAK TARTAR A,Celebi G,Sunnetcioglu M,KARABAY O,kumbasar karaosmanoglu h,SIRMATEL F,Tabak F In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey. Turkish Journal of Gastroenterology. 2022; 33(11): 971 - 978. 10.5152/tjg.2022.21834
IEEE Sarıgül F,User U,Didem sarı N,Kurtaran B,ONLEN Y,Şenateş E,Gunduz A,zerdali e,KARSEN H,Batirel A,KARAALİ R,GÜNER R,Yamazhan T,köse ş,Erben N,Ince N,Koksal I,Oztoprak N,Yörük G,komur s,Bal T,Yıldız Kaya S,bozkurt i,Gunal O,YILDIZ I,İNAN D,Barut S,NAMIDURU M,Tosun S,Türker K,Sener A,hizel k,Baykam N,Duygu F,Bodur H,Can G,GÜL H,SAĞMAK TARTAR A,Celebi G,Sunnetcioglu M,KARABAY O,kumbasar karaosmanoglu h,SIRMATEL F,Tabak F "In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey." Turkish Journal of Gastroenterology, 33, ss.971 - 978, 2022. 10.5152/tjg.2022.21834
ISNAD Sarıgül, Figen vd. "In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey". Turkish Journal of Gastroenterology 33/11 (2022), 971-978. https://doi.org/10.5152/tjg.2022.21834